Oleanolic Acid Triterpene Adjuvant for Marburg Vaccine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Marburg virus lack effective adjuvants that can stimulate a strong and lasting immune response, particularly in generating cytolytic T-lymphocytes (CTL) and Th1 responses, and existing adjuvants like QS-21 suffer from toxicity and stability issues.
Innovation Solution
An immunogenic composition comprising Marburg viral antigens combined with oleanolic acid triterpene adjuvants, which are designed to enhance IgG1 and T-cell responses, offering improved stability and reduced toxicity, and are capable of eliciting both humoral and cell-mediated immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing adjuvants like QS-21 are used to stimulate immune response, then immune response is enhanced, but toxicity increases
Solution Approach 1:
The patent extracts and isolates the specific active component (oleanolic acid triterpene) from the complex QS-21 adjuvant mixture. By taking out only the essential immunostimulatory component while removing other elements, the invention achieves immune response enhancement with reduced toxicity associated with the full QS-21 formulation.
Solution Approach 2:
The invention changes the chemical composition parameters of the adjuvant by using purified oleanolic acid triterpene instead of the complex saponin mixture in QS-21. This parameter change maintains the immunostimulatory function while altering the toxicity profile, resulting in a safer adjuvant formulation.
2Reliability
If existing adjuvants are used to generate strong immune response, then immune response is enhanced, but stability decreases
Solution Approach 1:
By extracting the stable oleanolic acid triterpene component from the less stable QS-21 mixture, the invention isolates the portion of the adjuvant that provides both immunostimulatory activity and compositional stability, eliminating the instability issues associated with the full QS-21 formulation.
3Object-affected harmful factors
If subunit vaccines are used to improve safety, then safety is enhanced, but immunogenicity decreases
Solution Approach 1:
The oleanolic acid triterpene adjuvant serves as an intermediary substance that bridges the gap between subunit vaccine safety and immunogenicity. It mediates the immune response by stimulating innate immunity and enhancing adaptive immune responses to the purified viral antigens, allowing subunit vaccines to achieve both safety and effectiveness.
Solution Approach 2:
The invention creates a composite vaccine formulation combining purified viral antigens (subunit component) with oleanolic acid triterpene adjuvant. This composite material integrates the safety advantages of subunit vaccines with the immunogenicity enhancement provided by the adjuvant, achieving both safety and strong immune response.
Data Source
AI summary
Methods and immunogenic compositions for generating an immune response against Marburg virus are provided. The immunogenic composition includes antigens obtained from a Marburg viral strain in combination with an oleanolic acid triterpene adjuvant.